title: [Diphosphonates and primary hyperparathyroidism].
authors.forename: N
authors.initials: N
authors.lastname: Conte
authors.forename: F
authors.initials: F
authors.lastname: Breda
authors.forename: R
authors.initials: R
authors.lastname: Di Virgilio
authors.forename: P
authors.initials: P
authors.lastname: Legovini
authors.forename: I
authors.initials: I
authors.lastname: Roiter
authors.forename: G
authors.initials: G
authors.lastname: Foscolo
authors.forename: G
authors.initials: G
authors.lastname: Caenaro
mesh_terms: D000236:Adenoma / Q000150:complications; D000328:Adult; D000368:Aged; D004002:Clodronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D010280:Parathyroid Glands / Q000473:pathology; D010282:Parathyroid Neoplasms / Q000150:complications; D013997:Time Factors
chemical_list: D004164:Diphosphonates; D004002:Clodronic Acid
vernacular_title: Difosfonati e iperparatiroidismo primitivo.